Skip to main content

Table 1 CHEK2*1100delC in breast cancer cases and healthy controls

From: Frequency of CHEK2*1100delC in New York breast cancer cases and controls

 

Positive for CHEK2*1100delC (%)

Controls

 

Jewish (New York)

3/1096 (0.3%)

Non-Jewish (New York)

2/569 (0.4%)

Total

5/1665 (0.3%)

BRCA1/2-negative individuals of mixed ethnicity with breast cancer from families with 3 or more cases of breast cancer

0/67 (0.0%)

BRCA1/2 Ashkenazi founder mutation-negative individuals with breast cancer from families with 3 or more cases of breast cancer

1/33# (3.0%)

BRCA2-negativei individuals of mixed ethnicity with male breast cancer

0/16 (0.0%)

Individuals with bilateral breast cancer of mixed ethnicity unselected for family history

0/46 (0.0%)

Individuals with unilateral breast cancer unselected for family history matched for age, ethnicity

1/46 (2.2%)

Clinic-ascertained individuals of Ashkenazi Jewish descent with bilateral breast cancer

1/46 (2.2%)

Clinic-ascertained individuals of Ashkenazi Jewish descent with unilateral breast cancer matched for age, family history

0/46 (0.0%)

  1. #This case previously reported in CHEK2 Breast Cancer Consortium [5].